ContractNovation Novation Agreement • April 30th, 2021 • Midatech Pharma PLC • Pharmaceutical preparations
Novation Novation Agreement Nov 2019 Midatech - Revised Execution Copy- Signed NOVATION This NOVATION AGREEMENT (this “Novation”) is entered into as of the 18th February 2019, by and among Novartis Pharma AG (“Novartis”), Midatech Limited (“the Institution”), and Secura Bio, INC (“SecuraBio”), (“Novation Effective Date”). WITNESSETH: WHEREAS, Novartis and the Institution have entered into the Licence Agreement effective as of 5 July 2017 (the “Agreement”), with respect to a licence involving the Novartis compound Panobinistat and certain patents associated therewith as defined under section 1.58 of the Agreement (“Licensed Patents”); WHEREAS, SecuraBio and Novartis have entered into a certain Asset Purchase Agreement, dated as of 19 February 2019 (the “Asset Purchase Agreement”), pursuant to which Novartis agreed to transfer and assign certain assets and business related to its compound Panobinistat and the Licensed Patents in the manner and on the terms as set out in the Agreement and
